@article{JTD17684,
author = {Leonhard Wert and Jasmin S. Hanke and Günes Dogan and Marcel Ricklefs and Anamika Chatterjee and Christina Feldmann and Issam Ismail and L. Christian Napp and Axel Haverich and Jan D. Schmitto},
title = {Argatroban administration as therapy for thrombosis in patients with continuous-flow ventricular assist devices},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 15},
year = {2017},
keywords = {},
abstract = {Background: Device thrombosis is one of the main complications in left ventricular assist devices (LVAD) therapy and remains a challenging issue. Data on device thrombosis management, especially on the application of direct thrombin inhibitors such as argatroban, is limited and a consensus on thrombosis management has not yet been established.
Methods: In this study we analysed retrospective clinical data obtained from 26 patients on VAD therapy who received argatroban for suspected VAD thrombosis, between April, 2012 and February, 2017.
Results: Thirteen patients (50%) showed resolution of thrombus after argatroban therapy. Eight of 26 patients (30.8%) were free of thrombotic events 90 days after discharge. Argatroban therapy was unsuccessful in 13 patients of the study cohort, leading to subsequent VAD-exchange. Six of 13 patients with first VAD-exchange had no thrombotic events 90 days after discharge. Six patients (23.1%) suffered from bleeding, especially gastrointestinal bleeding. No hemorrhagic strokes were observed. Three patients (11.5%) did not survive the follow-up period.
Conclusions: Argatroban appears to be an alternative to other pharmacological treatment options in VAD thrombosis. Efficacy and safety characteristics are acceptable, but further investigation on larger populations is necessary.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/17684}
}